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Abstract
Purpose To determine the protective eVect of gonadotropin-
releasing hormone analogs (GnRHa) using several ultrasound
and endocrine markers to detect ultrastructural ovarian
damage in Hodgkin’s lymphoma patients.
Methods Ten patients who had been treated for Hodg-
kin’s lymphoma and had received GnRHa to protect ovar-
ian function were matched with patients at similar age, who
had received the same chemotherapy regimens without
GnRHa. In addition, ten healthy women at the same age
were matched to the study groups to compare ovarian
markers. Blood samples were drawn to determine anti-
Müllerian hormone, Inhibin B, follicle-stimulating hor-
mone and transvaginal ultrasound scans were performed to
determine antral follicle count and ovarian volume. All
women were asked about their menstrual cycle pattern.
Results No diVerence was found when comparing the
ovarian parameters of both study groups. Compared with
healthy women, all ovarian parameters in the Hodgkin’s
lymphoma patients were signiWcantly diVerent.
Conclusions The results of this study demonstrate ultra-
structural ovarian damage in Hodgkin’s lymphoma patients
irrespective of GnRHa co-treatment. These Wndings do not
support previous studies, showing GnRHa to protect ovar-
ian function.
Keywords GnRH analogs · Chemotherapy · Ovarian 
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Introduction
Ovarian failure followed by amenorrhea and infertility is a
common side eVect of cytotoxic treatments for malignant
disease in women [1]. These treatments cause depletion of
the primordial follicle pool in a drug- and dose-dependent
manner [2]. To sustain fertility in young women undergoing
cytotoxic therapies, fertility preservation strategies have
been placed into the focus of interest of health professionals
and patients.
Among the currently discussed fertility preserving strat-
egies, the concept of administering a non-invasive medical
co-treatment such as gonadotropin-releasing hormone ana-
logs (GnRHa) seems very attractive [3]. Glode et al. [4]
using a murine model, tested this hypothesis for the Wrst
time almost three decades ago. They concluded that GnRHa
appeared to protect male mice from the gonadal damage
normally caused by cyclophosphamide, whereas several
investigators have demonstrated that GnRHa can inhibit
chemotherapy-induced ovarian follicular depletion in non-
human species, uncertainty remains regarding human appli-
cation [5].
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GnRHa in humans. As described in three recent meta-analyses
[6–8], the published clinical studies only provide evidence
but still do not prove statistically that GnRHa co-treatment
may reduce gonadal toxicity. This is due to the retrospec-
tive and non-randomized nature of most of the studies.
A recent prospective randomized controlled trial found that
the administration of GnRHa before and during chemother-
apy for breast cancer could preserve post treatment ovarian
function in young women [9].
However, more studies are needed. One reason is that
a biological plausibility for gonadal protection by
GnRHa in humans is still lacking [5] and another reason
is that most studies only describe the prevalence of
amenorrhea, even though depletion of primordial follicles
may occur despite maintenance of regular menstrual
cycles [10, 11]. The amount of surviving primordial fol-
licles after cytotoxic treatments can only be quantiWed in
vivo using several distinct hormonal and ultrasound-based
surrogates [12].
Therefore we set up this small, but carefully designed
trial with patients who were exactly matched for age and
treatment. A broad set of ultrasound parameters (antral fol-
licle count (AFC), ovarian volume) and endocrine markers
(follicle-stimulating hormone (FSH), anti-Müllerian hor-
mone (AMH), Inhibin B) were used to measure ovarian
reserve more precisely than simple prevalence of amenor-
rhea could do.
Materials and methods
This case-control study was performed at the Department
of Oncology together with the Department of Endocrinol-
ogy and Reproductive Medicine at the University Hospital of
Heidelberg (Germany) in cooperation with the German
Hodgkin Study Group (http://www.ghsg.org). The local ethics
review committee approved the study protocol and a written
informed consent was obtained from all patients.
Patient population
Ten patients who had received chemotherapy and radio-
therapy for Hodgkin’s lymphoma between 2001 and 2007
had been co-treated with GnRHa (leuprorelin 3.57 mg s.c
or goserelin 3.6 mg s.c. monthly before and during chemo-
therapy) to protect ovarian function (Group A).
In cooperation with the German Hodgkin Study Group,
we localized a total of 31 patients who had also been
treated for Hodgkin’s lymphoma in nearby University
Hospitals during the same period of time, but had not
received GnRHa. These patients were carefully matched
to our study group for age and a similar chemotherapy
regimen (Group B). Ten additional healthy women, who
were treated in our department of reproductive medicine
for severe male factor infertility, were matched to our
study groups by age to compare the ovarian markers
(Table 1).
The following chemotherapies were used: Four patients
received two cycles of ABVD (Adriamycin, Bleomycin,
Vinblasin, Dacarbacin), eight patients received four cycles
of ABVD, six patients received two cycles of OPPA
(Oncovin, Procarbacin, Prednison, Adriamycin) and two
cycles of COPP (Cyclophosphamid, Oncovin, Procarbacin,
Prednison) and two patients received eight cycles of BEA-
COPP-14 (Bleomycin, Etoposid, Adriamycin, Cyclophosph-
amid, Oncovin, Procarbacin, Prednison). All radiotherapies
were supradiaphragmal. At the time the study was performed,
all patients had completed their treatment cycles at least
6 months before.
Study protocol
All participating women were seen twice within a 1- to 3-
month period. Except the two patients with amenorrhea,
all women were seen at the second to Wfth day of the
cycle. No woman was taking oral contraception (OC) or
hormone replacement therapy (HRT) during the study
period. Blood samples were drawn to determine AMH,
Inhibin B and FSH in the serum and transvaginal ultra-
sound scans were performed to determine AFC and ovar-
ian volume. All women were asked about their menstrual
cycle pattern.
Treatment of the samples
Sera were obtained after centrifugation and stored at
¡80°C in Wve aliquots of 2 mL in standard Eppendorf
tubes. The samples were centrifuged for 10 min at 3,500 rpm.
Concentrations of FSH were analyzed using commercially
available immunoradiometric kits (Boehringer, Mannheim,
Germany) and analyzed on the Elecsys immunoassay analyzer
(Roche Molecular Biochemicals, Mannheim, Germany).
AMH was assayed using an ultra sensitive ELISA
(AMH/MIS active coated well ELISA, DSL-10-14400,
Diagnostic System Laboratories, DSL, TX, USA). The
assay range was 0.025–15 ng/mL, and the functional sensi-
tivity 0.017 ng/mL. Intra-assay and inter-assay coeYcients
of variance were 3.4 and 6.5%, respectively (conversion
factor to pmol/L = ng/mL £ 7.143). Inhibin B was quantiWed
with the Inhibin B active coated well ELISA, DSL-10-84100
(Diagnostic System Laboratories, DSL, TX, USA). The
assay range was 10–531 pg/mL, and the functional sensitivity
7 pg/mL. Intra-assay and inter-assay coeYcients of variance123
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protocol was followed in both cases. All assays were done
in duplicate.
Ultrasound scans
The ultrasound scans were performed via transvaginal
probe by the same investigator. The examining person
was blinded concerning hormonal status and medical
history of the patient. Antral follicles (2–12 mm) were
counted on both ovaries [13] and video monitored to
allow analysis by a second examiner. Ovarian volume was
calculated using the prolate ellipsoid formula L £ H £
W £ 0.523 (L = length in mid sagital, H = height in mid
sagital, W = width in axial) [14]. The volume of both ovaries
was added.
Outcome measures
The main outcome measures to compare the three study
groups were: secondary amenorrhea, FSH (U/L), AMH
(ng/mL), Inhibin B (pg/mL), AFC and ovarian volume
(cm3).
Statistical analysis
Mann–Whitney U test was used as a non-parametric test to
compare the parameters of ovarian reserve between the
Table 1 Comparison between Hodgkin’s lymphoma patients with (+) GnRHa and without (¡) GnRHa co-treatment and healthy women
Age age when study was performed, RT radio therapy, s supradiaphragmal radio therapy, IF involved Weld radio therapy, Mens menstrual cycle,
reg. regular, am. amenorrhea, AMH anti-Muellerian hormone, AFC antral follicle count, Ov-vol ovarian volume
Group Pat. ID Age Therapy 
(chemo-/IF-RT)
Mens FSH 
(U/L)
AMH 
(ng/mL)
Inhibin B 
(pg/mL)
AFC Ov-vol 
(cm3)
1 Healthy U.S 28 – reg. 9.2 3.2 73.3 11 9.3
Hod + GnRHa C.G 26 2£ ABVD/s reg. 6.4 4.3 23.2 12 13.6
Hod ¡ GnRHa J.F 30 2£ ABVD/s reg. 6.7 2.4 7.8 11 11.8
2 Healthy D.H 20 – reg. 5.3 5.4 79.5 19 12.6
Hod + GnRHa I.G 20 2£ ABVD/s reg. 8.1 1.9 23.6 0 3.1
Hod ¡ GnRHa I.H 23 2£ ABVD/s reg. 6.3 1.1 90.9 6 4.7
3 Healthy J.S 21 – reg. 3.3 5.9 76.5 10 9.3
Hod + GnRHa M.Mz 20 4£ ABVD/s reg. 5.9 1.5 11.5 5 7.1
Hod – GnRHa D.W 23 4£ ABVD/s reg. 5.5 3.0 8.5 16 8.0
4 Healthy N.B. 25 – reg. 6.9 4.1 79.5 12 7.5
Hod + GnRHa S.B. 25 4£ ABVD/s reg. 4.4 4.1 41.3 18 13.6
Hod – GnRHa S.O. 26 4£ ABVD/s reg. 3.7 1.5 5.4 9 5.9
5 Healthy J.R. 28 – reg. 5.6 3.7 74.2 14 6.6
Hod + GnRHa K.H 29 4£ ABVD/s reg. 2.4 1.6 2.1 0 6.7
Hod – GnRHa C.S. 27 4£ ABVD/s reg. 5.3 1.3 1.3 6 4.8
6 Healthy S.R. 30 – reg. 6.9 3.3 94.6 15 15.3
Hod + GnRHa N.K. 30 4£ ABVD/s reg. 6.0 1.5 18.6 3 5.7
Hod – GnRHa S.M. 33 4£ ABVD/s reg. 6.3 3.4 74.1 10 5.1
7 Healthy F.C. 18 – reg. 5.7 2.4 61.8 8 12.7
Hod + GnRHa L.K. 17 2£ OPPA + 2£ COPP/s reg. 5.6 0.5 11.3 6 13.3
Hod – GnRHa C.B. 17 2£ OPPA + 2£ COPP/s reg. 6.5 0.2 95.4 0 2.4
8 Healthy T.B. 19 – reg. 4.3 5.5 38.0 11 7.6
Hod + GnRHa E.H. 19 2£ OPPA + 2£ COPP/s reg. 10.0 0.0 0.0 4 1.6
Hod – GnRHa S.H. 27 2£ OPPA + 2£ COPP/s reg. 7.0 0.3 8.7 3 3.9
9 Healthy J.J. 21 – reg. 4.1 6.7 82.5 13 16.3
Hod + GnRHa K.F. 20 2£ OPPA + 2£ COPP/s reg. 26.2 0.2 11.2 8 8.2
Hod – GnRHa A.Sl. 22 2£ OPPA + 2£ COPP/s reg. 6.2 0.7 40.0 6 4.6
10 Healthy M.E. 34 – reg. 2.8 4.0 96.4 14 7.5
Hod + GnRHa N.S. 33 8£ BEACOPP-14/s am. 71.7 0.0 0.0 0 1.6
Hod – GnRHa E.P. 35 8£ BEACOPP-14/s am. 91.7 0.0 0.0 0 1.9123
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achieved for values of P · 0.05.
Results
Characteristics of trial participants
The mean age of patients treated for Hodgkin’s lymphoma
(Group A + B) was 25.1 [SD 5.2] years when the study was
performed (range 17–35 years). There was no signiWcant
diVerence in the mean age between Groups A and B (23.9
[SD 5.1] and 26.3 [SD 5.1] years). Mean age of the group of
healthy controls was 26.3 [SD 5.1] years (range 18–35 years).
Again no signiWcant diVerence was seen in the mean age
between the study groups (Group A + B) and the healthy
women. Both patients who had received BEACOPP-14 (one
in each study group) experienced secondary amenorrhea.
The time interval between the end of the chemotherapy
and the analysis of the ovarian parameters was 30.6 months
[SD 7.2] for Group A (range 19–45 months) and 32.2 months
[SD 20.4] for Group B (range 6–58 months). Patients
were not matched for this time interval for the following
reasons:
As the development of AMH producing secondary and
tertiary follicles takes only around 3 months, ovarian func-
tion is suYciently restored not later than 6 months after the
end of chemotherapy. Thereafter, AMH concentrations
remain stable in the same subject. The intra-individual vari-
ation of AMH is only 8% (coeYcient of variation) if AMH
is measured in the same subjects initially and again after
2 months according to an own unpublished study in 21
patients. For this reason and for the fact that other parame-
ters such as age and the type of chemotherapy are far more
important parameters to be matched, we accepted a limited
variation in the time interval between the end of the chemo-
therapy and the AMH measurement.
Outcome of study groups
No diVerence was found when comparing the ovarian
parameters in Hodgkin patients with (Group A) and without
(Group B) GnRHa co-treatment. For FSH, the mean con-
centration in Group A was 14.7 U/L [SD 6.6] and in Group
B 14.5 U/L [SD 0.9]. The mean concentration of AMH in
Group A was 1.6 ng/mL [SD 1.4] and in Group B 1.4 ng/
mL [SD 1.1]. For Inhibin B, the mean concentration in
Group A was 14.3 pg/mL [SD 8.7] and in Group B 33.2 pg/
mL [SD 12.5]. Moreover, no signiWcant diVerence was seen
for the mean AFC (Group A: 5.6 follicles [SD 5.5] and
Group B: 6.7 follicles [SD 4.7]) or the mean ovarian vol-
ume (Group A: 7.5 cm3 [SD 4.5] and Group B: 5.3 cm3 [SD
2.6]) in both groups (Fig. 1).
Compared with the healthy women of the control group,
all ovarian parameters in the Hodgkin’s lymphoma patients
(Group A + B) were signiWcantly diVerent. The mean con-
centration of FSH was signiWcantly higher in patients after
chemotherapy (14.6 U/L [SD 4.8] vs. 5.3 U/L [SD 1.8]).
The mean concentration of AMH and Inhibin B was signiW-
cantly lower in those women (1.5 ng/mL [SD 1.3] vs.
3.9 ng/mL [SD 1.2] for AMH and 23.7 pg/mL [SD 18.6]
vs. 64.9 pg/mL [SD 15.7] for Inhibin B). The AFC and the
ovarian volume were signiWcantly reduced in the Hodg-
kin’s groups as well (6.2 follicles [SD 4.5] vs. 11.6 follicles
[SD 2.9] for AFC and 6.4 cm3 [SD 3.8] versus 9.7 cm3 [SD
3.3] for ovarian volume). The P value for FSH was
P < 0.05 and for all other parameters P < 0.01 (Fig. 2).
Discussion
The concept of using GnRHa to prevent chemo- or radio-
therapy induced gonadal damage was introduced by Glode
et al. [4]. Since then, several animal studies suggested a
Fig. 1 Comparison of ovarian parameters in Hodgkin’s lymphoma
patients with (+) and without (¡) GnRHa co-treatment
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Arch Gynecol Obstet (2010) 282:83–88 87protective role of GnRHa co-treatment against follicle loss
during cytotoxic treatments. However, no beneWt could be
demonstrated against radiotherapy induced gonadal dam-
age [15, 16]. It has been highly debated whether human
application of GnRHa would be safe and useful to preserve
fertility and ovarian function in women treated for cancer
[5–7].
In a recent prospective randomized study including 80
women receiving chemotherapy for breast cancer, GnRHa
co-treatment was demonstrated to be eVective in preserving
ovarian function [9]. Patients were randomly assigned to
receive chemotherapy combined with monthly injections of
goserelin or chemotherapy alone. After 8 months of follow-
up, 89.6% of the women in the study group (with GnRHa)
resumed menses and 69.2% had spontaneous ovulation. In
contrast only 33.3% of the patients in the control group
(without GnRHa) resumed menses and 25.6% had sponta-
neous ovulation. These results were highly signiWcant
(P < 0.001). However, this study suVers from an important
shortcoming: The control group had signiWcantly higher
mean serum FSH and Estradiol (E2) levels even before start
of the treatment. As both are important endocrine markers
of ovarian reserve, a diVerence between the study groups
could be, at least in a part, due to a lower initial ovarian
reserve in the control group.
A second published prospective randomized study,
including 30 men and 18 women receiving chemotherapy
for Hodgkin’s disease, revealed that GnRHa treatment
seemed to be ineVective in preserving fertility as judged by
sperm count and menstrual function [17]. Patients were ran-
domly assigned to receive buserelin (20 men and 8 women)
prior to and for the duration of cytotoxic chemotherapy.
After 3 years of follow-up, all men in both, the study and
control, groups became oligo/azoospermic, while four of
the eight women treated with a GnRHa and six of the nine
female controls became amenorrheic.
In a third randomized study, Sverrisdottir et al. [18]
examined if goserelin as adjuvant treatment protects the
ovaries from premature failure in premenopausal breast
cancer patients. A total of 285 patients received CMF
(cyclophosphamide, methotrexate and 5-Xuorouracil). All
patients were randomly assigned to receive 2 years of gose-
relin, goserelin plus tamoxifen, tamoxifen alone or no
endocrine treatment. Endocrine treatment was given con-
comitant to chemotherapy. One year after completed CMF
and endocrine therapy, 36% of the women in the goserelin
group reported menses, compared to 7% in the goserelin
plus tamoxifen group, 13% in the tamoxifen group and
10% of the controls.
Several other non-randomized studies in the past pro-
vided mixed results [6]. In addition to the lack of consistent
support from clinical studies, there is currently no biologi-
cal explanation for how GnRHa can protect ovarian
reserve. Primordial follicles do not express FSH or GnRH
receptors [5]. GnRHa, in essence, returns the hormonal
milieu to prepubertal state. A clinical example for why
gonadal suppression may not protect ovaries is the fact that
prepubertal children receiving high-dose chemotherapy
given before hematopoietic stem cell transplantation still
suVer from ovarian failure [19]. Nevertheless, because
younger patients have a larger ovarian reserve, they might
tolerate some loss in the follicular pool, and immediate
ovarian function might not be aVected in the short term.
All patients who receive high-dose gonadotoxic chemo-
therapy will eventually suVer from premature ovarian
failure [20, 21].
In our study, a broad spectrum of Wve sensitive parame-
ters was used to analyze ovarian damage after cytotoxic
treatment more precisely than the simple determination of
secondary amenorrhea could do.
Only the two patients who had received the BEACOPP-
14 regimen experienced secondary amenorrhea, whereas all
other patients were still regularly menstruating. However,
using sensitive parameters to compare ovarian reserve in
Hodgkin’s lymphoma patients and healthy women, we
were able to demonstrate highly signiWcant diVerences.
This was also the case in those patients who had received
the ABVD regimen, which was thought not to aVect ovar-
ian reserve. According to our results, chemotherapy for
Hodgkin’s disease can, therefore, be considered to poten-
tially accelerate ovarian aging.
Furthermore, we could demonstrate ultrastructural ovar-
ian damage in Hodgkin’s lymphoma patients who were
co-treated with GnRHa. The ovarian damage was, according
to our parameters, identical to those patients who had not
received GnRHa. We thus conclude that GnRHa did not
seem to protect the ovaries from the cytotoxic eVect of the
chemotherapies in our setting.
Our Wndings are in concordance with the results of the
only other study using sensitive ovarian parameters to mea-
sure the ovarian reserve after chemotherapy and GnRHa
co-treatment. Giuseppe et al. [22] evaluated methods to
assess the ovarian reserve in 29 women with Hodgkin’s dis-
ease treated with chemotherapy. Furthermore, they exam-
ined the eVect of GnRHa co-treatment on ovarian function.
Ovarian reserve was studied by measuring the serum levels
of FSH, LH, Inhibin B, AMH and AFC following treatment
with or without GnRHa. They did not Wnd a signiWcant
diVerence of all parameters measured following GnRHa
treatment in comparison to the untreated control group.
Obviously the power of this study as well as of our study
is limited due to the low number of analyzed patients. How-
ever, analysing previous studies in detail reveals that a huge
number of patients are needed to draw distinct conclusions
concerning the eVect of GnRHa. The high number of diVer-
ent and heterogeneous chemotherapy regimes, the age123
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application of the rough parameter “amenorrhea” also lim-
its the power of the previously published prospective ran-
domized studies. Accurate matching of patients and
controls in relation to chemotherapy and age as well as the
application of several sensitive parameters to determine
ovarian reserve does allow drawing a conclusion irrespec-
tive of the small number of treated patients in our study. It
thereby contributes to the discussion about the eYciency of
GnRHa regardless of its design.
We could also demonstrate that only the application of a
broad set of sensitive parameters may properly reXect ovar-
ian reserve. Therefore, these markers may be used to better
quantify the damage of the ovaries following exposition to
chemotherapies in future studies. Such analyses may not
only require a prospective randomised design, but also the
determination of several sensitive ovarian markers to mea-
sure the supposed protective eVect of GnRHa on ultrastruc-
tural changes of ovarian function during cytotoxic
treatment. Such studies will hopefully Wnally solve the still
open question concerning the eYcacy of GnRHa as a fertil-
ity preserving technique.
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